Molecular and Cellular Underpinnings and Integrative Neuropathophysiology of Alzheimer’s Disease and Related Dementia (ADRD) – ZRG1 AN-Q 55
The ZRG1 AN-Q (55) special emphasis panel (SEP) reviews applications studying Alzheimer’s disease and related dementias (ADRD), including Parkinson’s dementia, Lewy body dementia (LBD), frontotemporal degeneration (FTD) and multi-etiology dementias. Focused areas include integrated and preclinical studies to understand molecular and cellular mechanisms underlying the pathogenesis, associated pathologies, and progression of pathological aging and ADRDs. Biomarkers of and therapeutic target identification and drug development for ADRD are also the topics covered by AN-Q (55). The main focus of this SEP is on preclinical studies using laboratory animals, although studies using a combination of animal and human tissues can be reviewed in AN-Q (55). With respect to approaches, AN-Q (55) reviews behavioral, protein signaling, genetic/genomic, epigenetic, small animal neuroimaging studies, etc.
Review Dates
Topics
- Genetic and epigenetic factors, including DNA damage and repair and roles of microRNAs in the pathogenesis, pathophysiology, and progression of ADRD and aging-associated neurodegeneration.
- Contribution of risk factor genes such as APOE alleles, TDP-43, APP, PS1, and MAPT, for the pathogenesis of ADRD.
- Cellular signaling mechanisms underlying aspects of ADRDs.
- The brain structural/functional (detected by neuroimaging) changes and behavioral manifestations for dysregulation of proteomics, proteostasis, endolysosomal pathway, and autophagy in ADRD
- Biomarkers of ADRD
- Small animal neuroimaging studies (sMRI, fMRI, PET, etc.) in ADRD.
- Use of iPSC and organoids as experimental tools in ADRD research
- Identification and testing of therapeutics, including small-molecule, gene, cell-based, and biologic therapies, and exercise interventions.
